Cargando…
Chemotherapy resumption in ovarian cancer patient diagnosed with COVID-19
• Chemotherapy resumption after convalescence from COVID-19 is safe and feasible. • No guidelines exist for resumption of chemotherapy in patients with COVID-19. • Cancer patients on chemotherapy may develop SARS-CoV-2 antibodies less frequently.
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7390730/ https://www.ncbi.nlm.nih.gov/pubmed/32766415 http://dx.doi.org/10.1016/j.gore.2020.100615 |
_version_ | 1783564501113634816 |
---|---|
author | Liontos, Michalis Kaparelou, Maria Karofylakis, Emmanouil Kavatha, Dimitra Mentis, Andreas Zagouri, Flora Terpos, Evangelos Dimopoulos, Meletios-Athanasios |
author_facet | Liontos, Michalis Kaparelou, Maria Karofylakis, Emmanouil Kavatha, Dimitra Mentis, Andreas Zagouri, Flora Terpos, Evangelos Dimopoulos, Meletios-Athanasios |
author_sort | Liontos, Michalis |
collection | PubMed |
description | • Chemotherapy resumption after convalescence from COVID-19 is safe and feasible. • No guidelines exist for resumption of chemotherapy in patients with COVID-19. • Cancer patients on chemotherapy may develop SARS-CoV-2 antibodies less frequently. |
format | Online Article Text |
id | pubmed-7390730 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-73907302020-07-30 Chemotherapy resumption in ovarian cancer patient diagnosed with COVID-19 Liontos, Michalis Kaparelou, Maria Karofylakis, Emmanouil Kavatha, Dimitra Mentis, Andreas Zagouri, Flora Terpos, Evangelos Dimopoulos, Meletios-Athanasios Gynecol Oncol Rep Case Report • Chemotherapy resumption after convalescence from COVID-19 is safe and feasible. • No guidelines exist for resumption of chemotherapy in patients with COVID-19. • Cancer patients on chemotherapy may develop SARS-CoV-2 antibodies less frequently. Elsevier 2020-07-30 /pmc/articles/PMC7390730/ /pubmed/32766415 http://dx.doi.org/10.1016/j.gore.2020.100615 Text en © 2020 Published by Elsevier Inc. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Case Report Liontos, Michalis Kaparelou, Maria Karofylakis, Emmanouil Kavatha, Dimitra Mentis, Andreas Zagouri, Flora Terpos, Evangelos Dimopoulos, Meletios-Athanasios Chemotherapy resumption in ovarian cancer patient diagnosed with COVID-19 |
title | Chemotherapy resumption in ovarian cancer patient diagnosed with COVID-19 |
title_full | Chemotherapy resumption in ovarian cancer patient diagnosed with COVID-19 |
title_fullStr | Chemotherapy resumption in ovarian cancer patient diagnosed with COVID-19 |
title_full_unstemmed | Chemotherapy resumption in ovarian cancer patient diagnosed with COVID-19 |
title_short | Chemotherapy resumption in ovarian cancer patient diagnosed with COVID-19 |
title_sort | chemotherapy resumption in ovarian cancer patient diagnosed with covid-19 |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7390730/ https://www.ncbi.nlm.nih.gov/pubmed/32766415 http://dx.doi.org/10.1016/j.gore.2020.100615 |
work_keys_str_mv | AT liontosmichalis chemotherapyresumptioninovariancancerpatientdiagnosedwithcovid19 AT kapareloumaria chemotherapyresumptioninovariancancerpatientdiagnosedwithcovid19 AT karofylakisemmanouil chemotherapyresumptioninovariancancerpatientdiagnosedwithcovid19 AT kavathadimitra chemotherapyresumptioninovariancancerpatientdiagnosedwithcovid19 AT mentisandreas chemotherapyresumptioninovariancancerpatientdiagnosedwithcovid19 AT zagouriflora chemotherapyresumptioninovariancancerpatientdiagnosedwithcovid19 AT terposevangelos chemotherapyresumptioninovariancancerpatientdiagnosedwithcovid19 AT dimopoulosmeletiosathanasios chemotherapyresumptioninovariancancerpatientdiagnosedwithcovid19 |